Insider Buying: Genocea Biosciences Inc. (GNCA) Insider Acquires $24,430.00 in Stock
Genocea Biosciences Inc. (NASDAQ:GNCA) insider Eric S. Hoffman purchased 7,000 shares of the company’s stock in a transaction dated Tuesday, November 8th. The shares were bought at an average cost of $3.49 per share, for a total transaction of $24,430.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Genocea Biosciences Inc. (NASDAQ:GNCA) opened at 4.45 on Monday. Genocea Biosciences Inc. has a 1-year low of $2.56 and a 1-year high of $8.07. The stock has a 50 day moving average of $4.17 and a 200-day moving average of $4.43. The company’s market cap is $126.09 million.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 54.25%. On average, equities research analysts predict that Genocea Biosciences Inc. will post ($1.64) earnings per share for the current year.
GNCA has been the topic of a number of recent analyst reports. FBR & Co reaffirmed a “buy” rating on shares of Genocea Biosciences in a report on Monday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, September 29th. Piper Jaffray Cos. dropped their price target on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, September 29th. Finally, Zacks Investment Research downgraded Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 19th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $12.35.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. bought a new position in Genocea Biosciences during the first quarter valued at $662,000. Schonfeld Strategic Advisors LLC bought a new position in Genocea Biosciences during the first quarter valued at $565,000. Ameriprise Financial Inc. bought a new position in Genocea Biosciences during the second quarter valued at $156,000. Dimensional Fund Advisors LP bought a new position in Genocea Biosciences during the second quarter valued at $143,000. Finally, Vanguard Group Inc. boosted its position in Genocea Biosciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 656,515 shares of the company’s stock valued at $2,691,000 after buying an additional 57,062 shares in the last quarter. 58.65% of the stock is currently owned by hedge funds and other institutional investors.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.